循环供者特异性抗HLA抗体是移植肾早期及加速纤维化的主要因素
该前瞻性队列纳入1539例肾移植受者,评估术后1年活检的间质纤维化和小管萎缩(IF/TA)。HLA-DSAs与严重IF/TA独立相关(aOR 1.53,95%CI 1.16-2.01),且在不伴抗体介导排斥的患者中仍显著(aOR 1.54,1.11-2.14)。HLA-DSAs是首要贡献因素(占11%),并关联微血管炎症、移植肾小球病、C4d沉积及移植物存活下降。
要点
- HLA-DSAs是严重IF/TA的独立危险因素,不依赖传统风险因素和抗体介导排斥。
- HLA-DSAs相关严重IF/TA患者微血管炎症、移植肾小球病和C4d沉积更重,移植物存活更差。
- 术后HLA-DSAs与IF/TA加速进展显著相关。
核心结论
- 循环HLA-DSAs是移植肾早期和加速纤维化的主要决定因素,独立于传统风险因素和抗体介导排斥。
研究设计与样本
- 前瞻性纳入两个中心连续1539例肾移植受者,评估术后1年活检的IF/TA,记录HLA-DSAs及传统决定因素,包括2260次原因活检的组织学诊断。
主要发现
- 498例(32%)患者存在严重IF/TA(Banff IF/TA grade 2或以上)。
- HLA-DSAs与严重IF/TA显著相关(调整比值比1.53;95%CI 1.16-2.01),纳入37个决定因素后仍显著。
- 在不伴抗体介导排斥的患者中,HLA-DSAs仍与严重IF/TA显著相关(调整比值比1.54;95%CI 1.11-2.14)。
- HLA-DSAs是首要贡献因素,涉及11%的病例;T细胞介导排斥、钙调神经磷酸酶抑制剂毒性、急性肾小管坏死、肾盂肾炎和BK病毒肾病分别涉及9%、8%、6%、5%和4%。
关键数值与推荐
- 严重IF/TA定义为Banff IF/TA grade 2或以上。
- HLA-DSAs与严重IF/TA的调整比值比为1.53(95%CI 1.16-2.01)。
- 不伴抗体介导排斥者中调整比值比为1.54(95%CI 1.11-2.14)。
临床怎么用
- 肾移植受者术后应监测HLA-DSAs,即使无抗体介导排斥,也需警惕其促进移植肾纤维化的独立风险。
- 对HLA-DSAs阳性者,应加强移植肾功能和组织学监测,关注微血管炎症、移植肾小球病和C4d沉积等改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Addressing the causes of kidney allograft-accelerated aging is an important challenge for improving long-term transplant outcomes. Here we investigated the role of circulating donor-specific anti-HLA antibodies (HLA-DSAs) in the development and the progression of kidney allograft fibrosis with inclusion of traditional risk factors for allograft fibrosis. We prospectively enrolled 1539 consecutive kidney recipients transplanted in two centers and assessed interstitial fibrosis and tubular atrophy (IF/TA) in biopsies performed at one year post-transplantation. The HLA-DSAs and all traditional determinants of IF/TA were recorded at transplantation and within the first year post-transplantation, including histological diagnoses in 2260 "for cause" biopsies. This identified 498 (32%) patients with severe IF/TA (Banff IF/TA grade 2 or more). HLA-DSAs were significantly associated with severe IF/TA (adjusted odds ratio, 1.53; 95% confidence interval 1.16-2.01) after including 37 determinants. HLA-DSAs remained significantly associated with severe IF/TA in patients without antibody-mediated rejection (adjusted odds ratio 1.54; 1.11-2.14). HLA-DSAs were the primary contributor, being involved in 11% of cases, while T cell-mediated rejection, calcineurin-inhibitor toxicity, acute tubular necrosis, pyelonephritis, and BK virus-associated nephropathy were involved in 9%, 8%, 6%, 5%, and 4% of cases, respectively. One hundred fifty-four patients with HLA-DSA-associated severe IF/TA showed significantly increased microvascular inflammation, transplant glomerulopathy, C4d deposition in capillaries, and decreased allograft survival compared to 344 patients with severe IF/TA without HLA-DSAs. Three hundred seventy-eight patients with post-transplant HLA-DSAs exhibited significantly accelerated progression of IF/TA compared to 1161 patients without HLA-DSAs in the biopsies performed at one year post-transplant and beyond. Thus, circulating HLA-DSAs are major determinants of premature and accelerated allograft fibrosis acting independently of traditional risk factors and antibody-mediated rejection.
引用
- Gosset C, Viglietti D, Rabant M, et al. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. Kidney Int. 2017. PMID: 28554738. doi:10.1016/j.kint.2017.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。